These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9644641)

  • 1. Neoral conversion from Sandimmune in maintenance renal transplant patients: an individualized approach.
    Curtis JJ; Lynn M; Jones PA
    J Am Soc Nephrol; 1998 Jul; 9(7):1293-300. PubMed ID: 9644641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
    Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
    Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
    Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
    Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to generic cyclosporine A in stable chronic patients after heart transplantation.
    Kraeuter M; Helmschrott M; Erbel C; Gleissner CA; Frankenstein L; Schmack B; Ruhparwar A; Ehlermann P; Katus HA; Doesch AO
    Drug Des Devel Ther; 2013; 7():1421-6. PubMed ID: 24348018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. NOVARTIS OLN-353 Study Group.
    Brennan DC; Barbeito R; Burke J; Brayman K; Greenstein S; Chang T
    Kidney Int; 1999 Aug; 56(2):685-91. PubMed ID: 10432409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
    Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
    Kahn D; Muller E; Pascoe M
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
    Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
    Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
    Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
    Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
    Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
    Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).
    Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G
    Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion.
    Pescovitz MD; First MR
    Transpl Int; 1998; 11 Suppl 1():S94-7. PubMed ID: 9664953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients.
    Thomas DW; Baboolal K; Subramanian N; Newcombe RG
    J Clin Periodontol; 2001 Jul; 28(7):706-9. PubMed ID: 11422595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of two different cyclosporine formulations on the long-term progression to chronic rejection in renal allograft recipients.
    Goel M; Flechner SM; Ischikawa A; Induhara R; Mastroianni B; Savas K; Modlin C; Goldfarb D; Feng J; Cook DJ; Novick AC
    Clin Transplant; 2002 Dec; 16(6):442-9. PubMed ID: 12437625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.